Mazindol is a sympathomimetic used to treat obesity in combination with lifestyle modifications. Mazindol is a tricyclic anorexigenic agent that is unrelated to and less toxic than amphetamine, but with some similar side effects.
- Mechanism
- Curator reviewed
Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release.
- Primary indication
- Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30...Curator reviewed
- Formula / weight
- C16H13ClN2O · 284.74 g/mol (avg)
- First approval
- Canada, 2015
- Code names
- 42-548 · AN 488 · DEA No. 1605
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
ZPXSCAKFGYXMGA-UHFFFAOYSA-NSMILESOC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1What you can answer from here — as of September 23, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Mazindol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account